The metabolic syndrome represents a clustering of risk factors that has been shown to predict adverse cardiovascular outcomes. Although the precise mechanisms contributing to the cardiometabolic syndrome (CMS) remain poorly defined, accumulating evidence identifies two intersecting candidate pathways responsible for inflammation and energy homeostasis in the pathophysiology that underlie cardiometabolic traits. Although currently no pharmacologic interventions specifically target CMS, future drug development efforts should attempt to capitalize on molecular nodes at the intersections of these pathways in the CMS.
|Number of pages||15|
|Journal||Endocrine, Metabolic and Immune Disorders - Drug Targets|
|State||Published - Jan 1 2010|
- Cardiometabolic syndrome
- Insulin resistance
- Metabolic syndrome
- Substrate metabolism